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Expression of mitochondrial
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Mark Schumacher2, Kimberly Topp2, Betty Smoot2,
Melissa Mazor1, Margaret Chesney2, Marilyn Hammer4,
Steven M Paul1, Jon D Levine2, and Christine Miaskowski1
Abstract
Background: Paclitaxel is one of the most commonly used drugs to treat breast cancer. Its major dose-limiting toxicity is
paclitaxel-induced peripheral neuropathy (PIPN). PIPN persists into survivorship and has a negative impact on patient’s
mood, functional status, and quality of life. No interventions are available to treat PIPN. A critical barrier to the development
of efficacious interventions is the lack of understanding of the mechanisms that underlie PIPN. Mitochondrial dysfunction has
been evaluated in preclinical studies as a hypothesized mechanism for PIPN, but clinical data to support this hypothesis are
limited. The purpose of this pilot study was to evaluate for differential gene expression and perturbed pathways between
breast cancer survivors with and without PIPN.
Methods: Gene expression in peripheral blood was assayed using RNA-seq. Differentially expressed genes (DEG) and
pathways associated with mitochondrial dysfunction were identified between survivors who received paclitaxel and did
(n¼ 25) and did not (n¼ 25) develop PIPN.
Results: Breast cancer survivors with PIPN were significantly older; more likely to be unemployed; reported lower alcohol
use; had a higher body mass index and poorer functional status; and had a higher number of lower extremity sites with loss
of light touch, cold, and pain sensations and higher vibration thresholds. No between-group differences were found in the
cumulative dose of paclitaxel received or in the percentage of patients who had a dose reduction or delay due to PIPN. Five
DEGs and nine perturbed pathways were associated with mitochondrial dysfunction related to oxidative stress, iron
homeostasis, mitochondrial fission, apoptosis, and autophagy.
Conclusions: This study is the first to provide molecular evidence that a number of mitochondrial dysfunction mechanisms
identified in preclinical models of various types of neuropathic pain including chemotherapy-induced peripheral neuropathy
are found in breast cancer survivors with persistent PIPN and suggest genes for validation and as potential therapeu-
tic targets.
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Introduction
Paclitaxel is one of the most commonly used drugs to
treat breast, ovarian, and lung cancers.1 Its major dose-
limiting toxicity is paclitaxel-induced peripheral neurop-
athy (PIPN). Prevalence rates for PIPN are extremely
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high, ranging from 59% to 87%.2,3 PIPN is character-
ized by paresthesias and dysesthesias that occur in a
“stocking-glove” distribution. PIPN persists into the
cancer survivorship period and has a negative impact
on individuals’ mood, functional status, and quality of
life (QOL).4 In particular, the negative impact of PIPN
on breast cancer (BC) survivors has been identified as a
gap in QOL for BC patients.5,6
Paclitaxel exerts its primary antitumor effects by
binding to beta-tubulin in microtubules, forming
extremely stable and nonfunctional microtubules that
results in apoptosis.7 In terms of its neurotoxic effects,
the exact mechanisms that underlie the development of
PIPN remain unclear. However, several lines of evidence
suggest that interruption of microtubule function in
neuron impairs axonal transport and results in a dying
back neuropathy. In addition, paclitaxel alters mito-
chondrial function through the depletion of mRNAs
that encode the mitochondrial fission/fusion machinery
in distal axons.8 This toxic effect leads to a deficit in
axonal energy supply and subsequent axonal
degeneration.9,10
Using the National Cancer Institute’s Common
Terminology Criteria for Adverse Events, PIPN of
grades 2 to 4 occurs at cumulative doses of between
715 and 1500mg/m2.11 However, not all patients who
receive this dose of paclitaxel develop PIPN. The wide
range in occurrence rates suggests that genetic factors
may play a role in the development of PIPN. While
preclinical studies suggest that a number of mecha-
nisms are involved in the development of PIPN,9,10,12
the majority of the genetic association studies of
PIPN evaluated for polymorphisms in candidate
genes that influence the metabolism and transport of
neurotoxic drugs. As noted in a recent systematic
review and meta-analysis of the molecular genetics of
chemotherapy-induced peripheral neuropathy
(CIPN),13 notable methodological issues, including
lack of standardization and detail in the phenotype
definition and acknowledgment of potential confound-
ing factors, prevented the authors from identifying any
candidate genes that were associated with CIPN in
general or PIPN specifically.
No studies were identified that evaluated for associ-
ations between changes in the expression of genes
involved in mitochondrial function and chronic PIPN
in cancer survivors. Given the preclinical evidence that
paclitaxel alters mitochondrial function in primary
afferent neurons,9,10 the purpose of this study was to
identify differentially expressed mitochondrial dysfunc-
tion (MD)-related genes and perturbed pathways in BC
survivors with (n¼ 25) and without (n¼ 25) chron-
ic PIPN.
Materials and methods
Survivors and settings
The methods for this study, which is part of a larger
study, are described in detail elsewhere.14 In brief, sur-
vivors were recruited from throughout the San Francisco
Bay area and met prespecified inclusion and exclusion
criteria (see Supplemental Material). The National
Coalition for Cancer Survivorship’s definition of
cancer survivor was used in this study (i.e., a person is
a cancer survivor from the moment of diagnosis through
the balance of life).15 Of the 1450 survivors who were
screened, 754 were enrolled and 623 completed the self-
report questionnaires and the study visit. Data from a
randomly selected sample of BC survivors with (n¼ 25)
and without (n¼ 25) chronic PIPN were used in
this analysis.
Study procedures
Research nurses screened and consented the survivors
over the phone, sent and asked them to complete the
self-report questionnaires prior to their study visit, and
scheduled the in-person assessment. At this assessment,
written informed consent was obtained, questionnaires
were reviewed for completeness, and objective measure-
ments were done. Blood samples were drawn, processed,
and stored for subsequent molecular analyses in
PAXgeneVR Blood RNA tubes (Qiagen, Inc.). This
study was approved by the institutional review board
of the University of California, San Francisco.
Study measures
Demographic and clinical characteristics. Survivors provided
information on demographic characteristics and com-
pleted the Alcohol Use Identification Test (AUDIT),16
Karnofsky Performance Status (KPS) Scale,17–19 and the
Self-Administered Comorbidity Questionnaire.20,21
Pain measures. Survivors with PIPN rated the intensity of
their pain using a 0 to 10 numeric rating scale and com-
pleted the pain interference scale from the Brief Pain
Inventory.22 The qualities of PIPN were evaluated
using the Pain Quality Assessment Scale.23,24
Objective measures of sensation. Light touch was evaluated
using Semmes Weinstein monofilaments.25 Cold sensa-
tion was evaluated using the Tiptherm Rod.26,27 Pain
sensation was evaluated using the Neurotip.27
Vibration threshold was assessed using a vibrometer.28
For all of the measures of sensation, both the upper and
lower extremities on the dominant side were tested.
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Balance. Self-report questions from the CIPN
Assessment Tool were used to assess the balance.29
The objective measures of balance were the timed get
up and go test (TUG)30 and the Fullerton Advanced
Balance (FAB) test.31,32
Phenotypic data analysis
Data were analyzed using SPSS version 23.33 Descriptive
statistics and frequency distributions were calculated for
survivors’ demographic and clinical characteristics. For
the four objective measures of sensation (i.e., light touch,
cold, pain, and vibration), composite scores, over all of
the sites that were tested on the dominant upper and
lower extremities, were created. For light touch, cold,
and pain, the number of sites with loss of each sensation
was summed. For vibration, the mean score across the
sites was calculated. Differences between the PIPN
groups in phenotypic characteristics and balance were
evaluated using independent sample t tests, v2 analyses,
Fisher’s Exact test (FET), and Mann–Whitney U tests.
A p value of <.05 was considered statistically significant.
RNA sample preparation
Total RNA was isolated using the PAXgeneVR Blood
miRNA Kit (Qiagen, Inc.) using established proce-
dures.34 Total RNA from the 50 survivors was sent to
the UC Davis Genomics Core Facility for library prep-
aration and for sequencing. Prior to library preparation,
600 ng of total RNA was treated with the Illumina
Globin-Zero Gold rRNA Removal Kit (Illumina Inc.,
San Diego, CA) to deplete cytoplasmic ribosomal
RNA35 and human globin mRNA.36,37 The globin/ribo
depleted RNA was cleaned with Agencourt RNAClean
XP (Beckman Coulter, Indianapolis, IN), and the
sequencing libraries were prepared with KAPA RNA
HyperPrep Kit (Roche Diagnostics Corp.,
Indianapolis, IN) according to the manufacturer’s pro-
tocol. Fourteen cycles of polymerase chain reaction
(PCR) amplification were used for double six base pair
index addition and library fragment enrichment.
Prepared libraries were quantified on a Roche
LightCycler 480II (Roche Diagnostics Corp.) using
KAPA Illumina library quantitative PCR reagents
(Roche Diagnostics Corp.).
RNA sequencing (RNA-seq)
Sequencing of the 50 samples was done on an Illumina
HiSeq 4000 apparatus (Illumina Inc., San Diego, CA).
All 50 samples were multiplexed into a single pool, with
each sample labeled with a dual-indexed adapter.38 The
sample pool was sequenced on four lanes for 100 cycles
of single-end reads with a 1% PhiX v3 control library
spike (Illumina Inc., San Diego, CA). Postsequencing
basecall files (bclfiles) were demultiplexed and converted
into an FASTQ file format using the bcl2fastq v2.17
software (Illumina Inc., San Diego, CA). Data were
posted and retrieved from a secured site hosted by the
Core Facility.
RNA-seq alignment, data processing, and
quality control (QC)
RNA-seq data processing was performed based on best
practices39,40 and our previous experience.34,41 Illuimina
adapters and leading or trailing low-quality bases were
removed, and reads with an average quality per base
below 15 in a 4-base sliding window or below a mini-
mum length of 36 bases were removed using trimmo-
matic.42 Individual samples were inspected with
FASTQC43 and in aggregate with MultiQC.44 After ini-
tial QC, 10 bases were trimmed from the beginning of
all reads and reads were reinspected with FASTQC.
The reference genome was prepared using the
GRCh38 assembly (gencode.v24.GRCh38.p5.fa).45
Transcriptome annotations were obtained from the
Gencode v24 primary assembly (gencode.v24.pri-
mary_assembly.annotation.gtf).45 Trimmed reads were
aligned to the annotated reference genome using the
Spliced Transcripts Alignment to a Reference aligner.46
Output SAM files were validated using ValidateSam.
Read groups were added to the SAM file using the
Picard tool AddOrReplaceReadGroups. Sorted BAM
files were inspected using RNA-SeQC47 and joined for
each sample. Abundance of RNA was estimated from
the combined aligned reads using featureCounts.48
Replicate count data were processed in edgeR.49
Ensembl50 transcripts were annotated with Entrez gene
ID and symbol.51 Lowly expressed tags were filtered out
by retaining only those with 3.27 reads per million (10/L
where L is the minimum library size in millions) in at
least 25 samples (i.e., the smallest group size). Count
estimates were normalized with the trimmed means of
M values (TMM) method.52 TMM normalization was
applied to the data set in edgeR using
calcNormFactors. Data were explored using multidi-
mensional scaling (MDS) plots for all samples to identify
sample outliers and potential batch effects due to tech-
nical artifacts (i.e., RNA integrity number (RIN), date
of RNA extraction). The same technician performed all
of the RNA extractions in one laboratory. Associations
between technical variables and PIPN group were
assessed using Fisher’s exact test or a generalized linear
model in R. Significance was assessed at a nominal p
value of .05. To evaluate the reproducibility of our meas-
urements,53 we utilized the one additional library54 that
was generated using an alternative preparation protocol
(i.e., without globin/ribo depletion step, but from the
same RNA materials) and sequenced in the same lane
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with the entire sample. We used the weighted kappa sta-
tistic to measure the agreement between the count data
of this sample produced by the two libraries.55 The count
data were summarized as log2 counts per million (after
TMM normalization) and grouped into 10 levels with a
range of 0 to 20 with a bin size of 2.
The technical variables that demonstrated an associ-
ation with PIPN group were flagged for subsequent eval-
uation with surrogate variable analysis (SVA). SVA was
used to identify variations that contributed to heteroge-
neity in the sample (e.g., batch effects) which were not
due to the variable of interest (i.e., PIPN group mem-
bership) or significant demographic covariates.56 To
identify which surrogate variables to include, all surro-
gate variables were tested for an association with the
phenotype and the retained technical variables.
Significance was assessed at a nominal p value of .05.
Any surrogate variable (SV) that was significantly asso-
ciated with the phenotype was excluded. Any remaining
surrogate variables that were significantly associated
with a technical variable were included as covariates in
the model for differential expression testing.
Differential expression (DE) analysis
Using edgeR, DE was determined under a variance
modeling strategy that addressed the overdispersion
observed in gene expression (GE) count data.57 EdgeR
is widely used for DE analysis and performs well relative
to other strategies.58,59 We followed published best prac-
tices60,61 and our previous experience.34,41 The total
sample size is 50 survivors. For this analysis, the overall
dispersion and the gene-wise and tag-wise dispersion
were estimated using general linear models estimated
using the Cox–Reid-adjusted likelihood method.62,63
Differences between the PIPN groups were tested using
likelihood ratio tests. Demographic and clinical charac-
teristics that differed between the PIPN groups, as well
as surrogate variables, were included as covariates in
the model. We assessed the significance of the
transcriptome-wide analysis to identify diffentially
expressed genes (DEGs) using a strict false discovery
rate (FDR) of 1% under the Benjamini–Hochberg
(BH) procedure and no minimal fold-change as evaluat-
ed by the topTags and p.adjust R functions.64,65
Pathway impact analysis
Pathway analysis approaches have been classified into
three classes or generations of approaches (reviewed in
66,67): overrepresentation analysis (ORA), functional
class scoring (FCS), and pathway topology-based
(PTB). ORA evaluates for the enrichment of DEGs in
a pathway. Although ORA are widely used, but are lim-
ited by the predefined set of input genes (i.e., the DE list
and the cutoff used to determine it), the statistic used is
independent of the measured changes, no differentiation
is made between the genes, and all pathways are consid-
ered independent. FCS addresses only the first three lim-
itations. In addition, both ORA and FCS consider
pathways as lists of genes (i.e., only the counts) and
ignore the additional information available in the path-
way representation (i.e., the topology). PTB approaches
utilize this additional information to evaluate for
biological-relevant interactions between genes in the
pathway (reviewed in Nguyen et al.68). Pathway impact
analysis (PIA) is a PTB that implements and impact
factor analytic approach, which includes potentially
important biological factors (e.g., gene–gene interac-
tions, flow signals in a pathway, pathway topologies)
as well as the magnitude (i.e., log fold-change) and the
significance (i.e., p values) of the biological differences
observed in the DE analysis.69 We used Pathway
Express70 to perform the PIA. This PTB impact factor
analysis approach is widely used and has 1200 citations
to date.68 The analysis included all genes (i.e., cutoff
free) and the DE analysis results (i.e., p value and log
fold-change) to determine the probability of a pathway
perturbation (pPERT). By including all genes in the
analysis, and using the DE analysis results to represent
the biological differences between the groups, we are
also able to capture the adjustments made for the demo-
graphic, clinical, and technical (i.e., SVs) variation in the
sample. A total of 208 signaling pathways were defined
using the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database.71 Sequence loci data were annotated
with Entrez gene IDs. The gene names were annotated
using the HUGO Gene Nomenclature Committee
resource database.72 We assessed for the significance of
the pathway analyses using a strict FDR of 1% under
the BH procedure.64,65
Results
Differences in demographic and clinical characteristics
As shown in Table 1, survivors with PIPN were signifi-
cantly older (p¼ .006) and were more likely to be unem-
ployed (p¼ .022). In terms of clinical characteristics (see
Table 2), survivors with PIPN had a lower AUDIT score
(p¼ .012), a higher body mass index (BMI; p¼ .017),
and a lower KPS score (p< .001). Of note, no
between-group differences were found in the total cumu-
lative dose of paclitaxel received or in the percentage of
patients who had a dose reduction or delay due to PIPN.
Pain characteristics
Table 3 summarizes the self-reported pain characteristics
of the survivors with PIPN. Worst pain severity was
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reported as 6.3 (2.1) of the 10, and the duration of
PIPN was 3.8 (3.9) years.
Differences in sensation
Survivors with PIPN had a higher number of lower
extremity sites with loss of light touch, cold, and pain
sensations (all, p< .05). Vibration thresholds were sig-
nificantly higher in the PIPN group (p¼ .009, Table 4).
Differences in balance
Survivors with PIPN were more likely to report trouble
with balance (p< .001) as well as higher severity and
distress (both p< .05) scores associated with balance
problems (Table 4). In addition, these survivors reported
worse TUG (p¼ .001) and worse FAB (p¼ .004) scores.
GE measurements
Mean RIN was 8.27 (minimum¼ 7.2), median
sequenced library size was 27,458,032, and median
aligned library size was 4,412,000 reads. The within-
replicate agreement (kappa¼ 0.82) was consistent with
high agreement measures observed in a recent study (i.e.,
0.62–0.81) that evaluated the variation of technical rep-
licates within RNA-seq data using non-clinical (i.e.,
Drosophila) samples.55 After QC filtering, 12,491 tran-
scripts were retained from the total of 60,725
GENCODE transcript targets. No samples were identi-
fied as outliers in the MDS plots. No batch effects were
identified for sample preparation order, RIN value, or
RNA processing date in the first four dimensions of
MDS plots. PIPN group was associated with the RNA
extraction date (FET p value¼ .01) but not with RIN
score or level. RNA extraction date was strongly asso-
ciated with one of the six identified surrogate variables.
This surrogate variable was included in the model as a
covariate to control for potential batch effects. The phe-
notype characteristics that were associated with PIPN
group membership (i.e., KPS, employment, age, BMI,
and AUDIT score) were included as covariates in the
model. The overall dispersion was observed to be 0.076
(biological coefficient of variation¼ 0.276), which is
lower than values reported in other clinical data sets.62
Using RNA-seq power,73 we estimate that with 25 rep-
licates in each condition (i.e., with and without PIPN),
an average depth of coverage of 15 million reads per
replicate, and the observed biological coefficient of var-
iation (i.e., 0.276), we are powered to detect 1.5-fold
changes for 83% of genes, and 2-fold changes for 99%
of genes, at a type I error rate of 0.01.
Differences in whole-transcriptome GE
The DE analysis included 11,487 genes. After correction
for multiple hypothesis testing at a conservative FDR of
1% (adjusted p value< .01), 20 genes were identified as
differentially expressed between the survivors with and
without PIPN. Of these, four genes were related to MD
(Table 5).
Successful annotation with ENTREZ IDs was per-
formed for 11,174 unique genes. Fold changes and
Table 1. Differences in demographic characteristics between breast cancer survivors with and without paclitaxel-induced neuropathy.
Characteristic
No neuropathy Neuropathy
Test, p value
50.0% (n¼ 25) 50.0% (n¼ 25)
Mean (SD) Mean (SD)
Age (years) 52.2 (9.5) 60.0 (9.4) t¼2.89, p¼ .006
Education (years) 16.6 (2.4) 16.3 (2.9) t¼ 0.32, p¼ .750
% (n) % (n)
Married/partnered 80.0 (20) 76.0 (19) FE, p¼ 1.000
Lives alone 16.0 (4) 12.0 (3) FE, p¼ 1.000
Employed 72.0 (18) 36.0 (9) FE, p¼ .022
Ethnicity
White 80.0 (20) 76.0 (19) FE, p¼ 1.000
Nonwhite 20.0 (5) 24.0 (6)
Annual household income
<$30,000 16.7 (4) 19.0 (4)
$30,000–$69,999 16.7 (4) 19.0 (4) U, p¼ .317
$70,000–$99,999 16.7 (4) 33.3 (7)
>$100,000 50.0 (12) 28.6 (6)
Child care responsibilities 25.0 (6) 20.0 (5) FE, p¼ .742
Adult care responsibilities 4.3 (1) 4.3 (1) FE, p¼ 1.000
FE: Fisher’s exact test; SD: standard deviation; U: Mann–Whitney U test.
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p values from the DE analysis for these genes were
included in the pPERT analysis of the 208 KEGG sig-
naling pathways. PIA identified 53 KEGG signaling
pathways that were significantly perturbed between the
PIPN groups after correction for multiple hypothesis
testing at a conservative FDR of 1% (adjusted pertur-
bation p value <.01). Of these, 10 KEGG signaling path-
ways were related to MD (Table 6; Figure 1).
Discussion
This study is the first to provide molecular evidence that
some of the mitochondrial mechanisms identified in pre-
clinical models of PIPN12,74,75 are found in cancer sur-
vivors. While a number of mechanisms are hypothesized
to underlie the development of PIPN,10 the mitotoxicity
hypothesis proposes that damage to primary afferent
sensory neurons leads to impairments in a variety of
mitochondrial functions.76 None of the previously pub-
lished candidate gene or genome-wide association stud-
ies identified any MD-related genes. In this study, we
found support for the differential expression of genes
and significant perturbations in a number of pathways
associated with MD including oxidative stress, iron
homeostasis, mitochondrial fission, and apoptosis and
autophagy.10
Oxidative stress
Mitochondria play a vital regulatory role in cellular
physiology. Within neurons, more than 90% of the
mitochondria are localized in axons where they are nec-
essary for energy generation.76,77 Paclitaxel opens the
mitochondrial permeability transition pore, which is
associated with increased generation of reactive oxygen
Table 2. Differences in clinical characteristics between breast cancer survivors with and without paclitaxel-induced peripher-
al neuropathy.
Characteristic
No neuropathy
50.0% (n¼25)
Neuropathy
50.0% (n¼25)
Test, p valueMean (SD) Mean (SD)
Karnofsky Performance Status score 92.9 (6.2) 80.0 (11.2) t¼ 5.02, p <.001
Body mass index (kg/m2) 23.5 (3.5) 27.2 (6.5) t¼2.50, p¼ .017
Number of comorbidities 1.3 (1.2) 1.5 (1.7) t¼0.55, p¼ .589
Self-Administered Comorbidity Questionnaire score 2.7 (2.7) 3.6 (4.2) t¼0.88, p¼ .384
AUDIT score 3.0 (1.7) 1.7 (1.8) t¼ 2.63, p¼ .012
Years since cancer diagnosis 4.2 (4.7) 4.6 (3.9) t¼0.34, p¼ .739
Number of prior cancer treatments 3.6 (0.8) 3.6 (0.8) t¼0.17, p¼ .863
Number of current cancer treatments 0.7 (0.7) 0.6 (0.7) t¼ 0.61, p¼ .543
Number of metastatic sites (out of seven) 1.0 (0.8) 0.6 (0.5) t¼ 1.72, p¼ .092
Number of metastatic sites without lymph node involvement 0.2 (0.6) 0.04 (0.2) t¼ 0.92, p¼ .365
% (n) % (n)
Smoker (ever) 37.5 (9) 32.0 (8) FE, p¼ .769
Exercise on a regular basis (% yes) 87.5 (21) 60.0 (15) FE, p¼ .051
Born prematurely (% yes) 0.0 (0) 12.5 (3) FE, p¼ .110
Comorbid conditions (% yes)
Osteoarthritis 8.0 (2) 28.0 (7) FE, p¼ .138
Back pain 28.0 (7) 24.0 (6) FE, p¼ 1.000
Depression 28.0 (7) 16.0 (4) FE, p¼ .496
High blood pressure 12.0 (3) 28.0 (7) FE, p¼ .289
Heart disease 0.0 (0) 4.0 (1) FE, p¼ 1.000
Diabetes 0.0 (0) 8.0 (2) FE, p¼ .490
Lung disease 4.0 (1) 4.0 (1) FE, p¼ 1.000
Anemia or blood disease 0.0 (0) 0.0 (0) Test not run
Ulcer or stomach disease 0.0 (0) 4.0 (1) FE, p¼ 1.000
Kidney disease 0.0 (0) 0.0 (0) Test not run
Liver disease 0.0 (0) 4.0 (1) FE, p¼ 1.000
Rheumatoid arthritis 0.0 (0) 4.0 (1) FE, p¼ 1.000
Total cumulative dose of taxol (mg/m2)** 782.8 (228.6) 814.7 (217.0) t¼ 0.14, p¼ .893
Patients who had a dose reduction or delay due to neuropathy (% (n))** 0.0 (0) 12.0 (3) FE, p¼ .235
Note: AUDIT: Alcohol Use Disorders Identification Test; FE: Fisher’s exact test; kg: kilograms; m2: meters squared; mg: milligrams; SD: standard deviation.
**Doses are reported as milligrams per meter squared.
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species (ROS).76 This type of oxidative stress leads to
structural and functional damage to mitochondria. In
animal studies, the administration of paclitaxel was asso-
ciated with the appearance of swollen and vacuolated
mitochondria in peripheral nerves and dorsal root gan-
glion (DRG) cells.12,78
In this study, we found differentially expressed genes
(i.e., peroxiredoxin 5 (PRDX5), glutaredoxin 5 (GLRX5))
and perturbed pathways (i.e., HIF-1 signaling pathway,79
PI3K-Akt signaling pathway,80 Peroxisome81) that are
regulated or mediated by oxidative stress. Several lines
of preclinical evidence support our clinical findings.
While not specifically evaluated in PIPN, in murine
models of peripheral nerve injury, the generation of ROS
is upregulated, and antioxidant pathways are downregu-
lated or functionally impaired.82,83 This redox imbalance
is enhanced by mitochondrial damage.84 However, most
neurons survive this imbalance, which suggests that
endogenous defense systems are activated to restore
homeostasis. Peroxiredoxin, glutaredoxins, and thiore-
doxins are part of this endogenous defense system that
remove ROS and mediate the response to the redox
stress.85 In one study that evaluated changes in mRNA
in DRG cell bodies and axons after unilateral sciatic
nerve injury (SNI),86 enriched mRNAs in the axonal
compartment on the side of the SNI included mitochon-
drial genes as well as genes of the peroxidase family
including Prdx5 (the rat homolog of human PDRX5,
which is downregulated in our survivors with PIPN in
this study).
In another study that evaluated the effects of
thioredoxin-fold proteins in an SNI model,87 while
both glutaredoxin (i.e., Glrx5) and peroxiredotoxins
(i.e., Prdx4, Prdx5) were found in the DRG, only
Prdx4 and Prdx5 were upregulated following the SNI.
Of note, Prdx5 upregulation was associated with an
increase in respective mRNA and protein accumulation
in peripheral fibers proximal to the injury. This finding is
consistent with an accumulation of mitochondria as a
result of blocked axonal transport.87 In addition, this
upregulation of Prdx5 was dependent on the presence
of endogenous HIF-1 (a perturbed pathway in our sur-
vivors with PIPN), a global regulator of oxygen homeo-
stasis that facilitates oxygen delivery and adaptation to
oxygen deprivation.88,89 The authors hypothesized that
failure of Prdx5 upregulation increases the risk for
chronic neuropathy.87 Interestingly, differences in
PDRX5 GE were observed in sural nerves from patients
with progressing compared to nonprogressing diabetic
neuropathy.90
Iron homeostasis
Perturbation in the ferroptosis pathway and the
decreased expression of GLRX5 was found in our
cancer survivors with PIPN. Ferroptosis is a regulated
cell death driven by lipid ROS91 and is characterized by
abnormal mitochondria morphology.92 Iron is an impor-
tant cofactor in metabolically active cells like neurons.
A carefully controlled supply of iron is needed for mito-
chondrial function, axonal transport, and myelina-
tion.93–95 While glutaredoxins (e.g., GLRX5) are
involved in redox reactions,85 they are needed for iron
homeostatsis.96,97 A growing body of evidence suggests
that alterations in mitochondrial iron metabolism are
Table 3. Pain characteristics of the breast cancer survivors with
paclitaxel-induced peripheral neuropathy.
Characteristic
Lower extremity
(n¼ 25)
Mean (SD)
Pain characteristics
Duration of neuropathy (years) 3.8 (3.9)
Pain now 3.1 (2.2)
Average pain 3.6 (2.0)
Worst pain 6.3 (2.1)
Days per week in pain 4.0 (3.2)
Hours per day in pain 13.0 (8.8)
Pain Interference Scale (0–10)
Walking ability 4.2 (3.2)
Balance 4.0 (3.1)
General activity 3.0 (2.9)
Enjoyment of life 2.9 (2.8)
Sleep 2.9 (3.0)
Normal work 2.8 (3.0)
Mood 1.9 (2.0)
Relations with other people 1.5 (1.9)
Sexual activity 0.8 (1.9)
Mean interference score 2.7 (2.2)
Pain Qualities Assessment Scale scores (0–10)
Numb 5.8 (3.0)
Tingling 4.8 (3.1)
Unpleasant 4.6 (2.3)
Dull 3.6 (3.3)
Intense 3.5 (2.5)
Electrical 2.9 (3.2)
Cramping 2.8 (3.3)
Aching 2.5 (2.6)
Hot 2.4 (3.1)
Radiating 2.3 (3.0)
Shooting 2.2 (3.1)
Sharp 2.0 (2.5)
Heavy 2.0 (2.7)
Tender 1.7 (2.3)
Throbbing 1.6 (2.6)
Sensitive skin 1.4 (1.8)
Itchy 1.0 (1.6)
Cold 0.9 (1.7)
Intense—surface pain 3.7 (3.0)
Intense—deep pain 3.5 (2.9)
SD: standard deviation.
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Table 4. Differences in sensation and balance measures between breast cancer survivors with and without paclitaxel-induced periph-
eral neuropathy.
Characteristic
No neuropathy Neuropathy
Statistic; p value
50.0% (n¼ 25) 50.0% (n¼ 25)
Mean (SD) Mean (SD)
Sensation measuresa
Light touch—lower extremity sites (out of nine)b 0.1 (0.3) 1.5 (1.5) t¼4.42, p <.001
Cold—lower extremity sites out of fourc 1.5 (1.3) 2.3 (1.0) t¼2.54, p¼ .014
Pain—lower extremity sites (out of nine)d 1.6 (1.6) 3.0 (2.1) t¼2.71, p¼ .009
Vibration—lower extremity sites (volts)e 16.2 (8.1) 25.1 (14.0) t¼2.76, p¼ .009
Balance measures
Trouble with balance (% yes (n))f 13.0 (3) 76.0 (19) FE, p <.001
Severity of balance trouble (0–10)g 1.7 (1.2) 5.6 (2.9) t¼4.16, p¼ .004
Frequency of balance trouble (0–10)h 2.3 (1.5) 5.1 (3.2) t¼2.37, p¼ .060
Distress from balance trouble (0–10)i 1.7 (1.2) 5.8 (3.2) t¼4.17, p¼ .003
Timed get up and go test (>13.5 s¼ higher risk for falls) 6.1 (1.1) 8.6 (3.1) t¼3.76, p¼ .001
Fullerton Advanced Balance test (25 is associated with a higher risk of falls) 38.0 (3.1) 33.4 (6.7) t¼ 3.14, p¼ .004
Note: FE: Fisher’s exact test; SD: standard deviation.
aChanges in sensation are reported for the dominant extremity.
bLower extremity sites for light touch were as follows: pad of great toe, pad of third toe, pad of fifth toe, base of heel, metocarpophalangeal (MP) joint of
great toe, MP joint of third toe, MP joint of fifth toe, midway along tibia, and patella.
cLower extremity sites for cold were as follows: top of great toe at first MP joint, pad of great toe, dorsum of foot midpoint, and medial malleolus.
dLower extremity sites for pain were as follows: pad of great toe, pad of third toe, pad of fifth toe, base of heel, MP joint of great toe, MP joint of third toe,
MP joint of fifth toe, midway along tibia, and patella.
eLower extremity sites for vibration were as follows: dorsal IP joint of great toe, medial malleolus, and patella.
fSince your chemotherapy, have you had trouble with your balance?
gAt its worst, how severe is the trouble with your balance (0¼ not at all severe to 10¼ extremely severe)?.
hHow often do you have trouble with your balance (0¼ never to 10¼ always)?
iAt its worst, how distressing is the trouble with your balance (0¼ not at all distressing to 10¼ extremely distressing)?
Table 6. Significantly perturbed mitochondrial dysfunction-related Kyoto Encyclopedia of Genes and Genomes pathways
between breast cancer survivors with and without paclitaxel-induced peripheral neuropathy.
Pathway ID Pathway name Total perturbation Adjusted pPerta
hsa04137 Mitophagy–animal 11.79 .004
hsa04150 mTOR signaling pathway 9.60 .004
hsa04152 AMPK signaling pathway 8.99 .004
hsa04151 PI3K-AKT signaling pathway 8.04 .004
hsa04066 HIF-1 signaling pathway 7.45 .004
hsa04216 Ferroptosis 6.98 .004
hsa04115 p53 signaling pathway 5.68 .007
hsa04146 Peroxisome 5.32 .007
hsa04068 FoxO signaling pathway 5.32 .008
hsa04218 Cellular senescence 5.36 .008
apPert: Perturbation p value adjusted using the Benjamini–Hochberg method.
Table 5. Differentially expressed mitochondrial dysfunction-related genes between breast cancer survivors with and without paclitaxel-
induced peripheral neuropathy (PIPN).
Ensemble gene ID Gene symbol Name Entrez ID logFCa Adjusted p valueb
ENSG00000126432 PRDX5 Peroxiredoxin 5 25824 0.987 .0098
ENSG00000182512 GLRX5 Glutaredoxin 5 51218 1.703 .0062
ENSG00000214253 FIS1 Fission, mitochondrial 1 51024 1.062 .0062
ENSG00000170315 UBB Ubiquitin B 7314 1.374 .0062
alogFC: Fold change of the log2 transformed normalized gene expression counts between the groups. A negative logFC denotes lower expression in
survivors with PIPN as compared to those without PIPN.
bp Value adjusted using the Benjamini–Hochberg method.
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involved in a number of neurological disorders (e.g.,
Parkinson’s disease) as well as in motor and cognitive
decline associated with aging.98 In addition, the products
of iron-regulatory and iron-transport-pathway genes
may play a role in the development of diabetic99,100
and HIV neuropathy.101
While no preclinical studies have identified an associ-
ation between CIPN and ferroptosis, an interesting find-
ing that warrants additional investigation is related to
the mitochondrial iron-binding protein called frataxin
(FXN). This protein is critical for mitochondrial iron
metabolism, overall cellular iron homeostasis, and anti-
oxidant protection.102–104 In an in vitro study of
CIPN,105 the administration of alpha-lipoic acid
increased the expression of frataxin in vehicle-treated
DRG cells as well as in DRG cells treated with paclitaxel
or cisplatin. The authors concluded FXN may play a key
role in neuroprotective pathways.
Mitochondrial fission
Mitochondrial fission is the process in which mitochon-
dria are divided into smaller units. Mitochondrial fission
Figure 1. Graph summary of pathway level statistics. (a) The measured expression change versus (b) perturbation accumulation in the
Mitophagy–Animal Kyoto Encyclopedia of Genes and Genomes pathway (hsa04137). The square nodes denote genes with gene expression
change, and the circle nodes denote all other nodes. The color of each node represents the perturbation (red¼ positive, blue¼ negative),
and the shade represents the strength of the perturbation. Note that the square nodes with no parents have no accumulation.
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enhances the number of mitochondria in neural cells and
helps to maintain their energy demands.77,106 Fission
mitochondrial 1 (FIS1, which was downregulated in sur-
vivors with PIPN) is a primary mediator of mitochon-
drial fission and has been implicated in MD and
autophagy.107,108 FIS1 recruits dynamin-related protein
1 (DLRP1/Drp1) from the cytosol, 109 which is the pri-
mary executor of fission.106 Defects in mitochondrial fis-
sion are implicated in a number of neurodegenerative
disorders (e.g., hereditary optic neuropathy,
Parkinson’s disease).106,110,111
Evidence from preclinical studies supports the associ-
ation found in our cancer survivors. In a study that eval-
uated whether Drp1 catalyzed the process of
mitochondrial fission, Sprague Dawley rats were treated
with 20,30-dideoxycitidine (ddC) or oxaliplatin.112 In this
study, intrathecal administration of an oligodeoxynu-
cleotide antisense against Drp1 resulted in a decrease
in its expression in peripheral nerves and markedly
attenuated neuropathic hyperalgesia associated with
both drugs. In a more recent study that evaluated the
role of Drp1 in neuropathic pain induced by perineural
human immunodeficiency virus gp120,113 intrathecal
administration of an oligodeoxynucleotide antisense
against Drp1 decreased mechanical allodynia and
decreased the spinal expression of increased Drp1 pro-
tein induced by gp120.
While not studied in terms of neuropathic pain, the
interconnection between mitochondria and the peroxi-
some (a perturbed pathway in our cancer survivors) is
an area of intense investigation.81,114,115 Peroxisomes
represent a class of ubiquitous and dynamic single mem-
brane bound organelles in eukaryotic cells.114
Substantial evidence suggests that peroxisomes and
mitochondria have a close functional interplay. In par-
ticular, peroxisomes and mitochondria contribute to
ROS homeostasis and share a redox-sensitive relation-
ship.114 It is plausible that this pathway could be
involved in PIPN.
Apoptosis and autophagy
Several signaling pathways involved in mitochondrial
apoptosis and autophagy (i.e., PI3K-Akt, mTOR,
FoxO, and AMPK) were perturbed in this study. In
terms of the PI3K/Akt/mTOR pathways, several lines
of evidence suggest that they are involved in the devel-
opment of neuropathic pain.116 For example, in a rat
model of chronic constriction injury (CCI),117 compared
to control and sham animals, increased mRNA expres-
sion and protein levels were observed for PI3K, Akt, and
mTOR in the CCI animals. In a more recent study that
evaluated for changes in PI3K/Akt signaling in spinal
cord slice preparations following CCI,118 PI3K/Akt sig-
naling increased in the L4-L6 spinal cord sections.
The authors concluded that PI3K/Akt signaling is
required for central sensitization in the CCI neuropathic
pain model.
The FoxO signaling pathway, that is regulated by the
PI3K, Akt, and mTOR signaling pathways,119 is a
potential target for a number of neurodegenerative dis-
orders 120 including diabetes.121 In a recent study that
evaluated for changes in genes and pathways associated
with neuropathic pain using a bioinformatics
approach,122 upregulated genes in the FoxO signaling
pathway were associated with spinal nerve ligation.
Recent evidence suggests that AMPK may be a
potential target for the treatment of chronic pain.123–
125 AMPK and peroxisome proliferator-activated recep-
tor c coactivator-1a (PGC-1a) signaling axes sense the
mitochondrial demands of the cell and regulate mito-
chondrial function.126 In a recent preclinical study,127
phosphorylation and expression of AMPK/PGC-1a
and mitochondrial chain complex proteins were down-
regulated in the DRG of streptozotocin-diabetic rats. In
addition, the administration of resveratrol (i.e., a poly-
phenol that augments APMK phosphorylation and
axonal growth128) was associated with the reversal of
thermal hypoalgesia, attenuation of foot skin intrader-
mal fiber loss and a reduction in myelinated fiber mean
axonal caliber in streptozotocin-diabetic rats. The
authors concluded that the development of neuropathy
was linked to nutrient excess and MD through defective
signaling of the AMPK/PGC-1a pathway. In terms of
CIPN, the coadministration of metformin (i.e., a widely
used antidiabetic drug that activates AMPK129) with cis-
platin or paclitaxel prevented the occurrence of mechan-
ical allodynia.130 In addition, metformin prevented the
cisplatin-induced increase in the latency to detect an
adhesive patch (a measure of sensory deficits) and the
reduction in the density of intradermal nerve fibers in
the paw.
Perturbations in the p53 signaling pathway were iden-
tified in our cancer survivors with PIPN. This pathway
regulates a complex transcriptional program involved in
a variety of biological processes, including cell cycle
arrest and apoptosis.131 Mitochondrial translocation of
the p53 molecule is associated with MD in a number of
neurological disorders.132,133 In terms of CIPN, cisplatin
treatment rapidly increased mitochondrial levels of p53
in DRG neurons as well as reduced mitochondrial mem-
brane potential and disrupted mitochondrial integrity
and function.134 In addition, the administration of the
mitochondrial protectant pifithrin-l (PFT-l; which pre-
vents the mitochondrial accumulation of p53) prevented
both paclitaxel- and cisplatin-induced mechanical allo-
dynia and sensory loss.135 Equally important, in other
studies, the administration of PFT-l protected against
loss of mitochondrial membrane potential,
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abnormalities in mitochondrial morphology, and func-
tional mitochondrial deficiencies in DRG
neurons.12,134,135
In the current study, perturbations in two-related
pathways (i.e., mitophagy and HIF-1 signaling) and
decreased expression of a related gene (i.e., ubiquitin)
were identified in survivors with PIPN. Ubiquitination
of mitochondrial proteins, including HIF-1A transcrip-
tion factor,136 regulates many aspects of mitochondrial
homeostasis including mitophagy.137 Mitophagy, a
selective form of autophagy, mediates the selective
removal of mitochondria138 and plays an essential role
in mitochondrial homeostatis.139 While no studies were
identified that found associations between CIPN and
ubiquitination or mitophagy, alterations in these two
processes are associated with neurodegeneration.140
Limitations
Several limitations warrant consideration. While our
sample size was relatively small, we had an extremely
well-characterized sample of BC survivors with and
without PIPN. Of note, no differences were found in
the total cumulative dose of paclitaxel that these survi-
vors received. Given that one cannot test for differences
in RNA in DRG neurons from living patients, as have
others evaluating for GE differences in patients with
painful neuropathies,141,142 we have evaluated for differ-
ences in RNA expression from peripheral blood.
Because our molecular analyses were done using blood
samples, we can only infer that the perturbations iden-
tified are consistent with changes within the peripheral
nervous system. Our findings warrant confirmation in an
independent sample. However, to decrease the possibil-
ity of spurious associations, we sequenced RNA to a
considerable depth, applied best practices for the
RNA-seq analyses, followed a strict QC procedure,
and evaluated for significance with a severely strin-
gent FDR.
Future research
This study is the first to provide molecular evidence that
a number of mitochondrial mechanisms identified in pre-
clinical models of various types of neuropathic pain,
including CIPN,12,74,75 are found in cancer survivors
with persistent PIPN. The limitations of the analyses
of RNA from blood and nonneural tissue notwithstand-
ing, we did observe differential profiles of expression and
perturbation in these processes, which suggest persistent
damage and/or changes in the regulation of mitochon-
dria. Future studies need to evaluate for differences in
epigenetic changes (i.e., methylation, microRNA)
between survivors with and without PIPN, which may
reflect changes in regulation patterns. In addition, our
findings suggest that chronic PIPN involves multiple
MD-related mechanisms. Therefore, studies are war-
ranted that evaluate for common and distinct MD-
related mechanisms associated with other neurotoxic
chemotherapy drugs (e.g., platinum, platinum, and
taxane combination). It must be acknowledged that a
cross-sectional study cannot demonstrate causality.
Longitudinal studies are needed that evaluate for
changes over time in the molecular mechanisms associ-
ated with CIPN. These longitudinal studies need to
include an in-depth characterization of the CIPN phe-
notype as well as pretreatment and multiple posttreat-
ment assessments of a number of molecular markers
(i.e., genes, GE, epigenetics). Translation of these find-
ings, if validated, may be accelerated by investigating
drugs that target mitochondrial function to be repur-
posed to treat CIPN.143 The use of sophisticated bioin-
formatics approaches and network analyses may allow
us to determine the timing of the disruptions in mito-
chondrial function associated with neurotoxic chemo-
therapy so that interventions can be initiated to
prevent this dose-limiting and devastating adverse effect.
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